OKYO PHARMA

Corporate Presentation

Disclaimer

- This presentation has been prepared by OKYO Pharma Limited (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company, its business and the industry in which it operates, and has not been approved by the United Kingdom Financial Conduct Authority, London Stock Exchange plc or otherwise. For the purposes of this notice, "presentation" means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed during the presentation meeting.
- This presentation may not be copied, distributed, reproduced or passed on, directly or indirectly, in whole or in part, or disclosed by any recipient, to any other person (whether within or outside such person's organisation or firm) or published in whole or in part, for any purpose or under any circumstances.
- The presentation has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person's respective directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in this presentation is subject to verification, correction, completion and change without notice. In giving this presentation, none of the Company or any of its parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person's respective directors, officers, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update this presentation or to provide the recipient with access to any further information that may arise in connection with it.
- This presentation does not constitute or form part of, and should not be construed as, any offer, invitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction and neither the issue of the information nor anything contained herein shall form the basis of or be relied upon in connection with, or act as an inducement to enter into, any investment activity. This presentation does not purport to contain all of the information that may be required to evaluate any investment in the Company or any of its securities and should not be relied upon to form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is not intended to provide complete disclosure upon which an investment decision could be made. The merit and suitability of an investment in the Company should be independently evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making an investment.
- To the extent available, the data contained in this presentation has come from official or third-party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the data contained in this presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the data contained in this presentation.
- This presentation and the information contained herein is not intended for publication or distribution in, and does not constitute an offer of securities in, the United States or to any U.S. person (as defined in Regulation S under the U.S. Securities Act of 1933 (the "Securities Act"), as amended, Canada, Australia, Japan, the Republic of Ireland, the Republic of South Africa or any other jurisdiction where such distribution or offer is unlawful. The Company has not registered and does not intend to register the offering in the United States or to conduct a public offering of any securities in the United States. Securities may not be offered or sold within the United States without registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain limited exceptions, neither this presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, into the United States, its territories or possessions. Any failure to comply with the foregoing restrictions may constitute a violation of U.S. securities laws. This presentation is only being provided to persons that are (i) "Qualified Institutional Buyers", as defined in Rule 144A under the Securities Act, or (ii) non-U.S. persons outside the United States, in compliance with Regulation S under the Securities Act. By attending this presentation or by reading the presentation slides, you warrant and acknowledge that you fall within one of the categories (i) and (ii) above.
- This presentation includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. The words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates, and include statements regarding the Company's planned pre-clinical studies and clinical trials, regulatory approval process, and demand for our product candidates are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by our forward-looking statements. These factors include, but are not limited to, the following: we have incurred significant net losses and anticipate that we will continue to incur significant net losses for the foreseeable future; we have never generated any revenue from product sales and may never be profitable; we will need to raise additional funding in the future, which may not be available on acceptable terms, or at all; we may not be able to obtain exclusivity or intellectual property rights for our product candidates or prevent others from developing similar competitive products. The forward-looking statements in this presentation are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. The Company expressly disclaims any obligation or undertaking to release any updates or revisions to these forward-looking statements to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based after the date of this presentation or to update or to keep current any other information contained in this presentation. Accordingly, undue reliance should not be placed on the forward-looking statements, which speak only as of the date of this presentation.
- By attending the meeting where this presentation is made or by accepting a copy of this presentation, you agree to be bound by the foregoing limitations and to maintain absolute confidentiality regarding the information disclosed in this presentation.

OKYO Pipeline

Major OKYO focus: OK-101 to treat Dry Eye Disease

Asset	Indication	Pre-Clinical	*IND-Enabling Studies	Phase 1	Phase 2	Phase 3
OK-101	Dry Eye	→	→	**Not Required	*Anticipated start date Q1-2023*	
	Uveitis	→				
	Allergic Conjunctivitis	→				
	Ocular Pain	→				
OK-201	Discovery Program					

**Anticipated IND Submission date Q4, 2022*

***Topical drug delivery*

Investment Highlights

Topically Delivered OK-101 Drug Candidate

- Novel mechanism of action: anti-inflammatory & pain reducing activity
- Inflammation and pain are the most common symptoms of dry eye
- Strong need for new drugs for dry eye disease
- Huge market potential for new drugs for dry eye disease

Rapid Clinical Development

- IND planned for Q4 2022
- First human trial planned as Phase 2 efficacy trial in dry eye disease patients
- Phase 2 planned to enroll first patient in Q1 2023
- Topline data anticipated in Q3, 2023
- Development time to approval: 4-5 years

Capital Efficient Program

- Able to skip Phase 1 safety trial and go directly to Phase 2 safety and efficacy trial in dry eye disease patients
- Short Phase 2 trial: n = 200-250
  Trial duration = 6-8 months
- $10 million to get to topline data for a $5 Billion dry eye market

Drug Candidate OK-101 to Treat Dry Eye Disease

***OK-101*: A lipid-conjugated chemerin peptide** *that targets a *GPCR receptor located on ocular immune cells involved in inflammation*

- *Novel mechanism-of-action – In vitro* and animal *studies indicate OK-101* ***exhibits both anti-inflammatory and ocular pain reducing activities***
- *Lipidated chemerin peptide chemistry* ***minimizes tear washout from ocular surface***
- *Administered topically, and is planned to go* ***straight from successful IND filing to Phase 2 efficacy trial*** *in dry eye disease patients*
- ***Rapid path to establishing efficacy -*** *should save time and capital on clinical development*

** GPCR = G-protein coupled receptor*

Chemerin- A Potential Regulator of Inflammation & Pain



- Chemerin, endogenous agonist of chemerin receptor ChemR23, activates immune cells at the inflammation site
- Smaller chemerin derived peptides can physiologically inhibit the inflammatory response of chemerin
- Topically administered OK-101 peptide can dramatically enhance the anti-inflammatory response

Proprietary MAP platform



Anti-Inflammatory Response

Immune Cells

Macrophages
T helper cells (Th)
Monocytes
Neutrophils

Novel membrane-anchored peptide (MAP) technology* enhances potency and increases drug residual time on the ocular surface

**OKYO has exclusive license for OK-101, a novel membrane-anchored chemerin peptide from OTTx Therapeutics, Boston that has potential to reduce ocular surface inflammation and ocular pain*

Membrane Anchoring Improves Potency, and Durability

In-vitro studies

Enhanced Potency

Human Chemerin Receptor



Increased Durability

Human Chemerin Receptor

(Wash Resistant)



*Adapted from Doyle J et al, J. Biol. Chem. 2014

Validation, Dry Eye Mouse Model



- Corneal permeability significantly reduced with OK-101 (0.04%) vs vehicle alone
- Potency of OK-101 was comparable to cyclosporine, an active ingredient of Restasis (Allergan)
- Reducing corneal permeability with OK-101 improves corneal integrity in dry eye mouse model

OK-101 Normalized Goblet Cells & Reduced Inflammatory CD4 T Cells

Increased mucin-secreting goblet cells

OK-101: (0.04%) normalized goblet cell density



Reduced Inflammatory Biomarkers

OK-101: (0.04%) reduced count of CD4+ T cells, which are known biomarkers of inflammation



OK-101: Potential Modulator of Ocular Pain

A significant proportion of dry eye patients suffer from “neuropathic ocular pain” with moderate to greater pain intensity.

* Ciliary Nerve Ligation Model

Ciliary nerve ligation surgery to create the corneal neuropathic pain (CNP) model



*Collaboration with Dr. Pedram Hamrah, Tufts Medical Center, Boston (Kenyon et al (2020) IOVS, Vol.61, 4085)

OK-101[1] reduced corneal pain response similar to gabapentin[2] (GBP), a commonly used drug for neuropathic pain



[1]Topical administration

[2]Administered by intraperitoneal injection

Dry Eye Disease: Overview

700,000,000
Worldwide patients

20,000,000
US patients

35%
+50 yrs old affected

Source: Papas et al. Ophthalmic Physiol Opt. 2021;41:1254
Farrand et al. AJO. 2017;182:90
Dana et al, AJO 2019, 202:47

OKYO PHARMA

Ocular Surface Damage

Lack of moisture and lubrication resulting in progressive damage to the ocular surface

Inflammation & Hyperpermeability

Inflammation and hyperpermeability leads to chronic symptoms of pain, itchiness, burning, and potential visual impairment

Dry Eye Disease Growth & Digital Screen Time

Long-term use of contact lenses and increasing digital screen time means the incidence of dry eye disease will continue to grow

Dry Eye Disease (DED) Market Opportunity

- Global DED* market approximately $5.22 billion in 2019 and expected to reach $6.54 billion by 2027.
- DED causes approximately $3.8 billion annually in healthcare costs and represents a major economic burden to public healthcare, accounting for more than $50 billion to the US economy annually.
- Present-day drugs inadequately treat DED arguing that a drug that is more effective will further increase market size.

*Market Research Report, Dry Eye Syndrome Market, FBI102413, Dec. 2020

Dry Eye: Standard of Care & Short Comings of Current Treatments

5 FDA approved drugs on market

	[1] Comments
Restasis (0.05% cyclosporine) Allergan	Delayed response, up to 6 months to improve symptoms, burning sensation when instilled **[2] 70% patients do not refill Rx at Month 12**
Xiidra (5% LFA-1 antagonist) Novartis	Eye irritation and burning sensation, change in taste **[2] 70% patients do not refill Rx at Month 12**
Cequa (0.09% Cyclosporine) Sun Pharma	Burning, pain upon instillation, blurry vision, UTI (side effects on label)
Eysuvis (0.25% Loteprednol) Kala Pharma	Short-term treatment only (maximum 2 weeks)
Tyrvaya 0.03 mg Varenicline/ inhalation Oyster Point	Sneezing, cough & throat irritation (side effects on label)

Short Comings of Current Drugs

- Inadequate efficacy
- Slow onset of action
- Several side effects of current drugs demand the need for more effective drugs to treat dry eye disease

The need for more effective drugs

[1] Side Effect profiles from Drug Labels, [2] White DE, (2020) Ocular Surgery News: Issue February 25, 2020

Investment Highlights

Topically Delivered OK-101 Drug Candidate

- Novel mechanism of action: anti-inflammatory & pain reducing activity
- Inflammation and pain are the most common symptoms of dry eye
- Strong need for new drugs for dry eye disease
- Huge market potential for new drugs for dry eye disease

Rapid Clinical Development

- IND planned for Q4 2022
- First human trial planned as Phase 2 efficacy trial in dry eye disease patients
- Phase 2 planned to enroll first patient in Q1 2023
- Topline data anticipated in Q3, 2023
- Development time to approval: 4-5 years

Capital Efficient Program

- Able to skip Phase 1 safety trial and go directly to Phase 2 safety and efficacy trial in dry eye disease patients
- Short Phase 2 trial: n = 200-250
  Trial duration = 6-8 months
- $10 million to get to topline data for a $5 Billion dry eye market

Drug Development Timelines

*Average time to clinically develop drug to FDA approval: 10.5 years



Potential OK-101 Development time to approval: 4 - 5 years

* BIO Report "Clinical Development Success Rates and Contributing Factors 2011-2220

FEBRUARY 15, 2022 - OKYO PRESS RELEASE

OKYO Pharma announces Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease

OK-101 First-in-Human Trial planned as Phase 2 Trial incorporating Primary Efficacy Endpoints covering Signs and Symptoms of Dry Eye Disease

Key points from press release:

- FDA concurred with OKYO's plan to pre-specify co-primary efficacy endpoints covering both a sign and symptom of dry eye disease in the planned DED Phase 2 clinical trial.
- Successful Phase 2 trial with pre-specified primary efficacy endpoints would accelerate timeline to new drug application (NDA).

OK-101 Development Timeline

- Skipping Phase 1
- Designing Phase 2 effectively as a Phase 3 registration trial



Investment Highlights

Topically Delivered OK-101 Drug Candidate

- Unique mechanism of action: anti-inflammatory & pain reducing activity
- Inflammation and pain are the most common symptoms of dry eye
- Strong need for new drugs for dry eye disease
- Huge market potential for new drugs for dry eye disease

Rapid Clinical Development

- IND planned for Q4 2022
- First human trial planned as Phase 2 efficacy trial in dry eye disease patients
- Phase 2 planned to enroll first patient in Q1 2023
- Topline data anticipated in Q3, 2023
- Development time to approval: 4-5 years

Capital Efficient Program

- Able to skip Phase 1 safety trial and go directly to Phase 2 safety and efficacy trial in dry eye disease patients
- Short Phase 2 trial: n = 200-250 Trial duration = 6-8 months
- $10 million to get to topline data for a $5 Billion dry eye market

Intellectual Property Portfolio

OK-101 Technology:

Comp. of Matter: US 10,233,219
- Issued in US to 2034 with potential patent term extension up to 2039

Dry Eye
- Method of Use: US 11,197,906
- Issued in US to 2034 with potential patent term extension up to 2039

Neuropathic Pain
- Method of Use: US11,254,720
- Issued in US to 2037

OK-201 Technology:

Comp. of Matter: US 10,899,796
- Issued in US to 2037 with potential patent term extension up to 2042

Dry Eye, Pain, Inflammation
- Method of Use: US 10,899,796
- Issued in US to 2037 with potential patent term extension up to 2042

- Allowed European Patent on Comp. of Matter and Use for neuropathic pain, ocular pain, ocular inflammation, or dry eye: EP3373947

Experienced Team With Considerable Drug Development Expertise

Management

Gary S. Jacob, PhD

Chief Executive Officer and Director

Co-inventor and developer of Synergy's FDA-approved drug Trulance, currently marketed by Bausch Health, Inc. 35 years of experience in the pharmaceutical and biotechnology industries.

Raj Patil, PhD

Chief Scientific Officer

30 years of academic/pharmaceutical R&D experience and leadership experience at Alcon, Novartis and Ora, all leaders in Ophthalmology

Keeren Shah

Chief Financial Officer

15 years of experience in financial planning and analysis, IPO offering and variety of finance positions at Visa Inc, Arthur Andersen and BBC Worldwide

Board

Gabriele Cerrone

Chairman

Extensive experience founding, financing, restructuring, and listing multiple micro-cap biotechnology companies in oncology, infectious diseases, and molecular diagnostics.

Gary S. Jacob, PhD

Chief Executive Officer and Director

35 years of experience in the pharmaceutical and biotechnology industries, R&D, operations, business development and capital financing activities

Willy Simon

Non-Executive Director

linternational banking experience gained in senior leadership positions at multiple financial institutions.

Bernard Denoyer

Non-Executive Director

Extensive financial management experience as Senior Vice President of Synergy Pharmaceuticals, Inc. Also served as Chief Financial Officer and Senior Vice President of META Group, Inc.

John Brancaccio

Non-Executive Director

Financial executive with extensive international and domestic experience in pharmaceutical and biotechnology companies

Dry Eye Disease
and Ocular Pain

OKYO Pharma Ltd.
55 Park Lane
London W1K 1NA

Tel: +44 (0) 207 495 237

OKYO Pharma U.S. Inc.
420 Lexington Avenue, Suite 1402
New York, NY, 10170 USA

Tel: +1 (917) 225-9646

Nasdaq: OKYO

LSE: OKYO

info@okyopharma.com